Ulcerative colitis

Oct 20, 2026

Nouscom Announces €120 Million Series D Funding and Upcoming Presentation of Long-Term Lynch Syndrome Clinical Data at ESMO; Viatris Announces FDA Approval of RYZUMVI for Presbyopia; Lilly’s Omvoh Meets Clinical Remission Endpoint in Children with Ulcerative Colitis; Estuary Biotherapeutics Debuts with $103 Million in Funding to Tackle Kidney Disease; Roche’s Enspryng Receives FDA Approval as a First-in-Class IL-6R Inhibitor for Thyroid Eye Disease

Jun 25, 2026

Top 7 Breakthrough Drugs for Ulcerative Colitis Treatment

Mar 17, 2026

5 Promising Exosome-based Therapies Paving the Way for Personalized Medicine

Nov 11, 2025

Cogent Biosciences’ Bezuclastinib Phase 3 PEAK Trial Positive Results for GIST; Domain Therapeutics Begins Phase I/II Trial of CCR8 Inhibitor DT-7012 in Solid Tumors; Anaptys Reports Negative Phase 2 Outcomes for Rosnilimab in Ulcerative Colitis; QOL Medical Strikes Deal to Acquire Evoke Pharma for $11 Cash Per Share; Eledon Pharmaceuticals, Inc. Unveils Phase 2 BESTOW Trial Data for Tegoprubart in Kidney Transplant Rejection Prevention at ASN Kidney Week 2025

Jul 14, 2025

How Novel Therapies Could Transform the Ulcerative Colitis Treatment Landscape

Jan 14, 2025

Agios’ PYRUKYND SNDA Accepted by FDA for Thalassemia; BridgeBio’s BBO-8520 Gets FDA Fast Track for KRASG12C-Mutated Lung Cancer; Nipocalimab Granted FDA Priority Review for Myasthenia Gravis; Rigel’s R289 Receives FDA Orphan Drug Designation for MDS; Rise Therapeutics Gets FDA IND Clearance for R-5780 in Cancer

Nov 26, 2024

FDA Grants Orphan Drug Designation for Ractigen’s RAG-21 in ALS; Intellia’s Nexiguran RMAT for ATTR Amyloidosis; FDA Approves Acoramidis for ATTR-CM; Jazz Wins FDA Approval for Ziihera in HER2-Positive Biliary Cancer; J&J Seeks FDA Approval for Subcutaneous TREMFYA in Colitis

Oct 15, 2024

Astellas & AviadoBio’s Exclusive Deal for AVB-101; GSK’s Depemokimab Shows Positive Results for Nasal Polyps; Lilly’s Mirikizumab Outperforms Ustekinumab in Crohn’s Study; TREMFYA Delivers Strong Results in Crohn’s & Colitis; ENHERTU Approved in China for HER2-Mutant NSCLC.

Sep 17, 2024

Johnson & Johnson’s TREMFYA Approved for Ulcerative Colitis; Roche’s Tecentriq Hybreza Approved as Subcutaneous Anti-PD-(L)1; OCREVUS ZUNOVO Receives Twice-a-Year Multiple Sclerosis Injection Approval; Lilly’s EBGLYSS Greenlit for Moderate-to-Severe Atopic Dermatitis; DUPIXENT Approved for Adolescents with Chronic Rhinosinusitis

Jul 12, 2024

Eli Lilly strengthening its Gastroenterology portfolio post Acquisition of Morphic. Tracking competitors and alliances in inflammatory bowel disease (IBD).

Newsletter/Whitepaper